TD Waterhouse Canada Inc. Has $14.71 Million Holdings in Becton, Dickinson and Company $BDX

TD Waterhouse Canada Inc. grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 96,211 shares of the medical instruments supplier’s stock after buying an additional 14,077 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Becton, Dickinson and Company were worth $14,715,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new position in Becton, Dickinson and Company in the 4th quarter valued at $26,000. Prosperity Bancshares Inc bought a new position in Becton, Dickinson and Company in the 4th quarter valued at $29,000. Meeder Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Finally, Tucker Asset Management LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter worth $34,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BDX shares. Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Bank of America upped their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Barclays boosted their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $187.67.

Insider Buying and Selling

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,105 shares of company stock valued at $1,590,208 in the last three months. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Down 1.5%

BDX opened at $184.78 on Friday. The firm has a 50 day simple moving average of $170.05 and a 200 day simple moving average of $160.69. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a market cap of $50.91 billion, a price-to-earnings ratio of 55.66, a price-to-earnings-growth ratio of 13.22 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the firm earned $3.68 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.